Kidney disease drug developer Variant has raised $10m from new strategic partner Incon in connection with a distribution agreement.
US-based orphan drug developer Variant Pharmaceuticals received $10m in equity financing from wireless technology producer Incon yesterday.
Founded in 2014, Variant is developing prescription drugs for rare medical conditions and diseases. Its lead drug candidate is hydroxypropyl beta cyclodextrin, which is set to treat two rare forms of kidney disease.
The company’s therapies are intended to remove causes of injury to the kidneys and delay progression of the disease in order to prevent the need for dialysis or a transplant.
…
